. 2025 Sep 12;9:e81912. doi: 10.2196/81912

Table 4.

Percentage of cohort participants reporting different experiences throughout by program month.

Experience	Month 1, n (%)		Month 3, n (%)		Month 6, n (%)		Month 12, n (%)
	Tirzepatide cohort (n=209)	Semaglutide cohort (n=130)	Tirzepatide cohort (n=209)	Semaglutide cohort (n=130)	Tirzepatide cohort (n=209)	Semaglutide cohort (n=130)	Tirzepatide cohort (n=209)	Semaglutide cohort (n=130)
Change in appetite	44 (21.1)	16 (12.3)	12 (5.7)^a	10 (7.7)	7 (3.3)^a	4 (3.1)	3 (1.4)^a	1 (0.8)^a
Illness	1 (0.5)	1 (0.8)	3 (1.4)	3 (2.3)	2 (1)	3 (2.3)	0 (0)	0 (0)
Intervention benefits	26 (12.4)	26 (20)	29 (13.9)	17 (13.1)	10 (4.8)	14 (10.8)	14 (6.7)	4 (3.1)
Negative experience	0 (0)	1 (0.8)	0 (0)	0 (0)	0 (0)	1 (0.8)	0 (0)	0 (0)
Neutral experience	27 (12.9)	20 (15.4)	41 (19.6)	24 (18.5)	68 (32.5)^a	42 (32.3)^a	109 (52.2)^a	65 (50)^a
Other	21 (10)	9 (6.9)	20 (9.6)	10 (7.7)	35 (16.7)	2 (1.5)	13 (6.2)	6 (4.6)
Other priorities	6 (2.9)	4 (3.1)	10 (4.8)	2 (1.5)	6 (2.9)	1 (0.8)	4 (1.9)	3 (2.3)
Positive experience	130 (62.2)	90 (69.2)	98 (46.9)^a	70 (53.8)	83 (39.7)^a	65 (50)^a	66 (31.6)^a	51 (39.2)^a
Reduced effectiveness or slow progress	0 (0)	1 (0.8)	0 (0)	0 (0)	1 (0.5)	0 (0)	0 (0)	0 (0)

^aP<.001.